menu
    • menu
    [{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Esperion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"HLS Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Tablet, Film Coated","sponsorNew":"HLS Therapeutics \/ HLS Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"HLS Therapeutics \/ HLS Therapeutics"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HLS Therapeutics \/ HLS Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"HLS Therapeutics \/ HLS Therapeutics"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Amarin","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HLS Therapeutics \/ Amarin","highestDevelopmentStatusID":"10","companyTruncated":"HLS Therapeutics \/ Amarin"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"HLS Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"HLS Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"HLS Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"HLS Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Porcine recombinant Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"HLS Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"HLS Therapeutics \/ HLS Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"HLS Therapeutics \/ HLS Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by HLS Therapeutics

    Menu

    HLS Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bempedoic Acid,Ezetimibe

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Esperion Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL and NEXLIZET in Canada

                            Details : HLS Therapeutics for the exclusive rights to commercialize Nexletol and Nexlizet in Canada for cardiovascular disease.

                            Product Name : Nexlizet

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 08, 2025

                            Lead Product(s) : Bempedoic Acid,Ezetimibe

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Esperion Therapeutics

                            Deal Size : $5.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HLS Therapeutics Announces Promotional Agreement with Pfizer for Vascepa® in Canada

                            Details : Under terms of the Agreement, Pfizer will deploy a team across Canada to support education about Vascepa with primary care physician ("PCP") groups.

                            Product Name : Vascepa

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 16, 2021

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Amarin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HLS Therapeutics Reports Positive Data from Covid-19 Outpatient Trial

                            Details : Vascepa COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while demonstrating a 25% reduction in high-sensitivity C-reactive protein with encouraging short-term safety and tolerability data using Vascepa lo...

                            Product Name : Vascepa

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 14, 2020

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Amarin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HLS Therapeutics Announces Health Canada Approval of PERSERIS® for the Treatment of Schizophrenia

                            Details : Health Canada has approved HLS Therapeutics' PERSERIS® (risperidone for extended-release injectable suspension), 90 mg and 120 mg subcutaneous injection, a novel long-acting injectable of risperidone, for the treatment of schizophrenia in adults.

                            Product Name : Perseris

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 17, 2020

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Porcine recombinant Factor VIII

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $49.3 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            HLS Therapeutics Acquires Portfolio of Four Royalty Interest, Gains Takeda's Obizur

                            Details : HLS has acquired certain entities that hold the rights to a diversified portfolio of royalty interests on global sales of four different products, this includes Takeda Pharmaceutical's Obizur, a porcine recombinant Factor VIII for acquired hemophilia A.

                            Product Name : Obizur

                            Product Type : Protein

                            Upfront Cash : $30.8 million

                            September 30, 2020

                            Lead Product(s) : Porcine recombinant Factor VIII

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $49.3 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            HLS Therapeutics

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HLS Therapeutics Files New Drug Submission for PERSERIS® in Canada

                            Details : If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia.

                            Product Name : Perseris

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 23, 2020

                            Lead Product(s) : Risperidone

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth